Korro Bio publishes corporate deck outlining RNA-editing pipeline for hyperammonemia and alpha-1 antitrypsin deficiency
KRRO•Cash position and runway
Cash, cash equivalents, and marketable securities totaled $137.9 million as of June 30, 2026, with runway projected into H2 2028.
Pipeline and development priorities
Korro Bio outlined value-creation priorities centered on RNA editing therapies that do not permanently modify DNA.
- KRRO-111 was named as a development candidate for a GalNAc-conjugated alpha-1 antitrypsin deficiency program.
- Regulatory clearance to start a first-in-human trial for KRRO-121 is targeted for H2 2026.
- A third GalNAc-conjugated liver development candidate is expected in H2 2026.
